Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 23, 2015

Primary Completion Date

June 11, 2019

Study Completion Date

June 11, 2019

Conditions
Alzheimer's Disease
Interventions
DRUG

[18F]GTP1

Participants will receive \[18F\]GTP1 as per the schedule specified in the arm description.

Trial Locations (16)

18104

Lehigh Center Clinical Research, Allentown

30033

NeuroStudies.net, LLC, Decatur

30303

Emory University, Atlanta

32806

Bioclinica Research, Orlando

33137

Miami Jewish Health Systems, Miami

33912

Neuropsychiatric Research; Center of Southwest Florida, Fort Myers

43537

Advanced Medical Research, Maumee

06510

Molecular NeuroImaging, New Haven

06905

KI Health Partners, LLC; New England Institute for Clinical Research, Stamford

04401

Acadia Clinical Research; Dr. Henderson's Office, Bangor

02360

Donald S. Marks, M.D., P.C.; Medical Center, Plymouth

02169

Alzheimers Disease Center, Quincy

07856

NeuroCognitive Institute, Mount Arlington

08755

Bio Behavioral Health, Toms River

02914

Rhode Island Mood & Memory Research Institute, East Providence

02906

Butler Hospital, Providence

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY